Medical Marijuana Could Stop Alzheimer’s Development
A recent study has scientists wondering if THC, the psychoactive component of cannabis, could cure Alzheimer’s. The study found that THC is a catalyst for removing toxic plaque in the brain, and serves as an inflammation blocker; in each role, preventing common features of the neurodegenerative disease.
“It is reasonable to conclude that there is a therapeutic potential of cannabinoids for the treatment of Alzheimer’s disease,” David Schubert, senior researcher and a professor at Salk Institute for Biological Studies, wrote.
One supporter of Schubert’s research is Keith Fargo, the director of scientific programs for the Alzheimer’s Association. Fargo, too, acknowledges marijuana’s therapeutic potential for Alzheimer’s patients, calling the drug a “legitimate avenue of research.”
Dr. Donovan Maust, is another medical researcher who has studied medical marijuana as a treatment for dementia.
An assistant professor of psychiatry at the University of Michigan, Maust called Schubert’s results “interesting,” but does not believe it is enough to begin using marijuana as a treatment for the disease.
“It is difficult to say what, if any, effect this might have in humans, even if it would successfully promote clearance of [plaque],” he said.
Several studies and patient interviews have found that medical marijuana is successful in easing the behavioral symptoms, confusion, and agitation that Alzheimer’s patients experience. But, scientists are hoping to discover evidence that medical marijuana can serve as an effective preventative treatment, or even a cure, for Alzheimer’s.
For Schubert, the lack of treatment for Alzheimer’s disease can be attributed to two things: the disease causes very complex damage to the brain and research is too narrowly focused. He sought to take a broader approach to Alzheimer’s research about 10 years ago, with a drug candidate he derived from curcumin, the main ingredient of turmeric.
After extensive research, Schubert and his team found that their drug, J147, worked through the body’s endocannabinoid system, which told them that the drug had a cannabinoid-like effect. This was motivation enough to begin investigating THC as a possible preventative treatment for Alzheimer’s. Schubert and his team found that THC prevents the accumulation of plaque and the death of nerve cells and stopped brain inflammation.
Fargo claimed that the most important part of Schubert’s study is that “it gives us a better understanding of the cannabinoid system”
and how preventing nerve cell death could impede Alzheimer’s progression. While Schubert would like to continue investigating cannabinoids, government regulations on marijuana research make doing so nearly impossible.
“It’s much harder than it should be to do research on medical marijuana and the cannabinoids it contains,” said Dr. David Casarett, a researcher at Duke University. Casarett believes that the best thing the government could due to improve medical marijuana research, is to reclassify the plan as a Schedule II or III drug.